Compare NetEase Inc (NTES) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs Tango Therapeutics Inc. — how do they compare? NetEase Inc trades at $124.91 (market cap $79.76B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: NetEase Inc is far larger — about 21.3× Tango Therapeutics Inc.'s market cap, and NetEase Inc pays a 2.35% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetEase Inc for 73 Days and Tango Therapeutics Inc. for 0 Days on average.
| NTES | TNGX | |
|---|---|---|
Market Cap | $79.76B | $3.75B |
Volume | 503,697 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $152.85 | $32.90 |
52-Week Low | $109.26 | $7.50 |
Typical Hold Time | 73 Days | 0 Days |
Enterprise Value | $55.44B | $2.77B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTES trades at $123.73, down 1.34% on the day, with a bullish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $4.4 billion, an 8% year-over-year increase, though EPS missed expectations. Strong fundamentals include a 27.88% net income margin and robust cash flow from operations of $50.74 billion in 2025. Recent news highlights global expansion and AI investments as key growth drivers.
The outlook remains positive with an 81.82% analyst buy rating and a consensus price target of $168.00, implying significant upside. Key risks include earnings volatility, competitive pressures in gaming, and macroeconomic sensitivity. The stock's current valuation at a P/E of 16.58 offers a reasonable entry point for long-term growth investors.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
